CAMBRIDGE, Mass.--(BUSINESS WIRE)--RaNA Therapeutics, a leading biotech developing a new class of revolutionary RNA-targeted medicines, today announced RaNA's CEO Ronald Renaud will present a corporate overview at the JMP Securities Life Science Conference at 4:30 p.m. EST on Tuesday, June 21, 2016, at the St. Regis New York.
On June 16, the company will also present a poster titled “A Novel Epigenetic Approach to Treat SMA” at Cure SMA’s Annual SMA Research Conference in Anaheim, California. Sponsored by Cure SMA annually since 1988, the conference aims to bring together leading spinal muscular atrophy researchers, clinicians and families living with the disease.
About RaNA Therapeutics
RaNA Therapeutics is a leading biotechnology company committed to the development of next generation RNA-targeted medicines that selectively upregulate gene expression to increase endogenous protein levels for therapeutic benefit. The company was founded by preeminent global leaders who pioneered the relationship between lncRNA and chromatic modifiers, as well as breakthrough oligonucleotide technologies. RaNA’s mission is to improve the lives of people suffering from serious life-altering diseases by creating precision medicines that can change the course of their condition. RaNA’s technology has broad therapeutic potential to treat a wide range of diseases, including rare genetic disorders. The company has current lead programs in spinal muscular atrophy and Friedreich’s ataxia. For more information about the company and its platforms, please visit www.ranarx.com.